CD200 immune checkpoint reversal at the site of tumor vaccine inoculation: A novel approach to glioblastoma immunotherapy
Z. Xiong, E. Ampudia-Mesias, G. E. Pluhar, S. K. Rathe, D. A. Largaespada, Y. Y. Sham, C. L. Moertel, M. R. Olin
This paper demonstrates that a CD200 peptide inhibitor enhances immune response in glioblastoma by reversing tumor-induced immunosuppression and downregulating PD-1 receptors.
bioRxiv · Aug 6, 2019 · PreprintCancer Biology